Skip to content

No results found

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

XLO Xilio Therapeutics, Inc. Common Stock
$8.48 2.40% +0.20
Notify me if price changes either direction
Interactive Brokers Logotype

Buy XLO stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 49.6M
Enterprise value -81020880
Trailing PE -2.0322196523443
Forward PE -14.775862
PEG Ratio 0.00029797942116486
Enterprise to EBITDA 2.003
Enterprise to revenue -1.851
Price to book MRQ 1.100835
Price to sales TTM 1.1322972

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2025-12-31
Revenue (TTM) 43.8M
EBITDA -40441000
Diluted EPS TTM -4.19
Total Cash (MRQ) 137.5M
Current ratio (MRQ) 2.577
Operating Cash Flow (TTM) -4992000

XLO trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent XLO News

Home

No results found

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.